Related Experiment Video
Updated: Jun 11, 2026

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
Strain-dependent serotonin neuron feedback control: role of serotonin 2C receptors
Eleonora Calcagno1, Roberto W Invernizzi
1Istituto di Ricerche Farmacologiche Mario Negri, Laboratory of Neurochemistry and Behavior, Department of Neuroscience, Milano, Italy.
Abstract:
We investigated the role of serotonin(2C) receptor-mediated feedback mechanisms in the response to citalopram in C57BL/6 and DBA/2 mice, which are respectively responders and non-responders to selective serotonin reuptake inhibitors in the forced swimming test. The microdialysis technique was used to assess changes in extracellular serotonin and GABA in the mouse dorsal raphé (DR). Citalopram (1.25-20 mg/kg) raised extracellular serotonin and GABA in the DR of both mouse strains. These effects were abolished by depleting brain serotonin with p-chlorophenylalanine (300 mg/kg × 3). Systemic and/or intra-DR infusion of the serotonin(2C) receptor antagonist 6-chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-indoline (1 mg/kg and 0.1 μM, respectively) enhanced citalopram's effect on extracellular serotonin in the DR and medial prefrontal cortex and abolished the rise of GABA in the DR of DBA/2 mice but had no effect in C57BL/6 mice. The serotonin(2C) receptor agonist Ro60-0175 (0.03-3.0 mg/kg) reduced extracellular serotonin and raised GABA in the DR of DBA/2 mice but had much less effect in C57BL/6 mice. These findings show that the sensitivity of serotonin(2C) receptors determines the efficacy of augmentation strategies aimed at enhancing the effect of serotonin reuptake inhibitors on extracellular serotonin through the suppression of serotonin(2C) receptor-mediated feedback control of serotonin neurons.
Insights
Serotonin(2C) receptor sensitivity dictates antidepressant response. Blocking these receptors enhances citalopram
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Selective serotonin reuptake inhibitors (SSRIs) are widely used antidepressants.
- The role of serotonin(2C) receptors in SSRI efficacy is not fully understood.
- Mouse strain differences (C57BL/6 responders vs. DBA/2 non-responders) offer a model to study SSRI response variability.
Purpose of the Study:
- To investigate the role of serotonin(2C) receptor-mediated feedback in citalopram's effects.
- To compare these mechanisms in SSRI-responsive and non-responsive mouse models.
- To determine if modulating serotonin(2C) receptors can enhance SSRI efficacy.
Main Methods:
- Utilized microdialysis to measure extracellular serotonin and GABA in the dorsal raphe (DR) of mice.
- Administered citalopram, a serotonin(2C) receptor antagonist, and a serotonin(2C) receptor agonist (Ro60-0175).
- Depleted brain serotonin using p-chlorophenylalanine to confirm drug mechanisms.
Main Results:
- Citalopram increased serotonin and GABA in the DR of both mouse strains.
- Serotonin(2C) receptor antagonism enhanced citalopram's effects in non-responders (DBA/2 mice).
- Serotonin(2C) receptor agonism decreased serotonin and increased GABA in non-responders.
Conclusions:
- Serotonin(2C) receptor sensitivity is a key determinant of SSRI efficacy.
- Targeting serotonin(2C) receptors via antagonism may enhance antidepressant effects in non-responders.
- Understanding these feedback mechanisms can inform the development of more effective antidepressant strategies.
Related Concept Videos
G-protein Coupled Receptors
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs Affecting Neurotransmitter Release or Uptake
Feedback Regulation of Calcium Concentration
Various transmembrane receptors, such as G protein-coupled receptors (GPCRs), elicit a response to extracellular signals by increasing cytosolic calcium. Activated GPCRs...
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with one...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs